Jun 2026 (Q2 FY26) — Aug 6, 2026
DENTSPLY SIRONA Q2 FY26 — Return-to-Growth Plan Progress Amidst Macro Headwinds
Read the full callDentsply Sirona (XRAY) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Dentsply Sirona earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 898 | −4.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 9.1 | +22.8 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 37.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$8.42 −1.75% · −$0.15
Performance −32.7% 1Y
1Y: $12.51 on 17 Oct 2025 → $8.42. High $14.68 (27 Feb 2026), low $8.42 (19 Oct 2026).
- Previous close
- $8.57
- 52-week range
- $8.42 – $14.68
- One year
- −34.88%
Overview
- Symbol
- XRAY
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Dentsply Sirona earnings calls (XRAY)
Financials
What the filings say
Net profit, year on year: +182% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 951 | 905 | 879 | 936 | 904 | 961 | 880 | 898 |
| Operating profit | -462 | -509 | 63 | -128 | -218 | -139 | -35 | 82 |
| Operating margin | −48.6% | −56.2% | 7.2% | −13.7% | −24.1% | −14.5% | −4.0% | 9.1% |
| Interest | 18 | 16 | 19 | 24 | 23 | 22 | 24 | 22 |
| Profit before tax | -478 | -523 | 44 | -153 | -230 | -147 | -42 | 72 |
| Tax rate | −3.6% | 18.2% | 56.8% | 71.2% | −86.1% | 1.4% | 76.2% | 50.0% |
| Net profit | -494 | -430 | 20 | -45 | -427 | -146 | -10 | 37 |
| EPS ($ per share) | -2.46 | — | 0.10 | -0.22 | -2.14 | — | -0.05 | 0.18 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 1,226 | 1,404 | 1,198 | 1,514 | 456 | 205 | -835 | -1,564 |
| Total liabilities | 3,554 | 3,508 | 4,415 | 4,242 | 3,831 | 4,076 | 3,810 | 4,089 |
| Fixed assets | 871 | 802 | 791 | 773 | 761 | 800 | 766 | 861 |
| Total assets | 8,687 | 8,603 | 9,350 | 9,239 | 7,643 | 7,370 | 5,753 | 5,429 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 500 | 639 | 649 | 657 | 517 | 377 | 461 | 235 |
| Cash from investing | -253 | -69 | -1,106 | -358 | -138 | -89 | -197 | -132 |
| Cash from financing | -250 | -472 | 476 | -379 | -329 | -307 | -302 | -80 |
| Net cash flow | -11 | 95 | 33 | -99 | 26 | -31 | -62 | 54 |
| Capital expenditure | -183 | -123 | -87 | -142 | -149 | -149 | -180 | -131 |
| Free cash flow | 317 | 516 | 562 | 515 | 368 | 228 | 281 | 104 |
Insider filings
63 filings between Nov 24, 2025 and Aug 10, 2026.
Open market
decisions to buy or sellPurchases
$1.74M
12 purchases by 9 insiders
Sales
$915.7K
1 sale by 1 insider
Compensation
not trading decisions- 34
- Award — granted as compensation
- 14
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| LUCIER GREGORY T | $894.1K | $915.7K | Mar 9, 2026 |
| Barber Michael J | $150.0K | — | Jun 11, 2026 |
| Forbes James D | $129.7K | — | Mar 9, 2026 |
| MAZELSKY JONATHAN JAY | $101.4K | — | Jun 12, 2026 |
| MCKEON BRIAN P | $101.2K | — | Jun 12, 2026 |
| Gladden Brian T | $100.0K | — | Jun 15, 2026 |
| VARON LESLIE F | $100.0K | — | Nov 24, 2025 |
| HOLDEN BETSY D | $99.7K | — | Jun 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Fortson John C. EVP & CFO | Award | 24,014 | $0 |
| Aug 7, 2026 | Frohning Andrea L. SVP, CHRO | Tax withheld | 802 | $9.7K |
| Jun 15, 2026 | HOSEIN CLYDE Director | Purchase | 6,500 | $64.9K |
| Jun 15, 2026 | Gladden Brian T Director | Purchase | 9,985 | $100.0K |
| Jun 12, 2026 | MAZELSKY JONATHAN JAY Director | Purchase | 10,000 | $101.4K |
| Jun 12, 2026 | MCKEON BRIAN P Director | Purchase | 10,000 | $101.2K |
| Jun 11, 2026 | Barber Michael J Director | Purchase | 15,175 | $150.0K |
| Jun 11, 2026 | HOLDEN BETSY D Director | Purchase | 10,086 | $99.7K |
| Jun 3, 2026 | HOLDEN BETSY D Director | Award | 22,822 | $0 |
| Jun 3, 2026 | Forbes James D Director | Award | 28,887 | $0 |
| Jun 3, 2026 | Gladden Brian T Director | Award | 22,822 | $0 |
| Jun 3, 2026 | LUCIER GREGORY T Director | Gift | 38,382 | $0 |
| Jun 3, 2026 | MCKEON BRIAN P Director | Award | 28,887 | $0 |
| Jun 3, 2026 | LUCIER GREGORY T Director | Gift | 38,382 | $0 |
| Jun 3, 2026 | Zurbay Donald Director | Award | 22,822 | $0 |
| Jun 3, 2026 | Vergis Janet S. Director | Award | 22,822 | $0 |
| Jun 3, 2026 | MAZELSKY JONATHAN JAY Director | Award | 22,822 | $0 |
| Jun 3, 2026 | LUCIER GREGORY T Director | Award | 38,382 | $0 |
| Jun 3, 2026 | HOSEIN CLYDE Director | Award | 22,822 | $0 |
| Jun 3, 2026 | Barber Michael J Director | Award | 22,822 | $0 |
| Jun 3, 2026 | VARON LESLIE F Director | Award | 22,822 | $0 |
| May 22, 2026 | Scavilla Daniel T President, CEO & Member of BOD | Tax withheld | 4,095 | $41.8K |
| Mar 9, 2026 | LUCIER GREGORY T Director | Purchase | 15,000 | $186.7K |
| Mar 9, 2026 | Forbes James D Director | Purchase | 5,000 | $62.4K |
| Mar 4, 2026 | Scavilla Daniel T President, CEO & Member of BOD | Award | 145,089 | $0 |
| Mar 4, 2026 | Czerney Kevin VP, Chief Accounting Officer | Award | 13,690 | $0 |
| Mar 4, 2026 | Johnson Robert Anthony SVP, Chief Supply Chain Office | Award | 44,643 | $0 |
| Mar 4, 2026 | Denti Aldo Mariano Roberto EVP, Chief Commercial Officer | Award | 59,524 | $0 |
| Mar 4, 2026 | Frohning Andrea L. SVP, CHRO | Award | 26,786 | $0 |
| Mar 4, 2026 | Johnson Robert Anthony SVP, Chief Supply Chain Office | Tax withheld | 1,026 | $13.8K |
| Mar 4, 2026 | Frohning Andrea L. SVP, CHRO | Tax withheld | 690 | $9.3K |
| Mar 4, 2026 | Czerney Kevin VP, Chief Accounting Officer | Tax withheld | 328 | $4.4K |
| Mar 3, 2026 | Czerney Kevin VP, Chief Accounting Officer | Tax withheld | 1,197 | $15.9K |
| Mar 3, 2026 | Czerney Kevin VP, Chief Accounting Officer | Tax withheld | 527 | $7.0K |
| Mar 3, 2026 | Johnson Robert Anthony SVP, Chief Supply Chain Office | Tax withheld | 3,229 | $42.9K |
| Mar 3, 2026 | Johnson Robert Anthony SVP, Chief Supply Chain Office | Tax withheld | 4,481 | $59.6K |
| Mar 3, 2026 | Frohning Andrea L. SVP, CHRO | Tax withheld | 1,977 | $26.3K |
| Mar 3, 2026 | Frohning Andrea L. SVP, CHRO | Tax withheld | 2,990 | $39.8K |
| Mar 3, 2026 | LUCIER GREGORY T Director | Purchase | 22,445 | $314.9K |
| Mar 3, 2026 | Forbes James D Director | Purchase | 5,000 | $67.3K |
| Mar 2, 2026 | Frohning Andrea L. SVP, CHRO | Award | 8,861 | $0 |
| Mar 2, 2026 | Czerney Kevin VP, Chief Accounting Officer | Award | 1,478 | $0 |
| Mar 2, 2026 | LUCIER GREGORY T Director | Purchase | 27,555 | $392.5K |
| Mar 2, 2026 | Johnson Robert Anthony SVP, Chief Supply Chain Office | Award | 9,599 | $0 |
| Feb 24, 2026 | Scavilla Daniel T President, CEO & Member of BOD | Tax withheld | 1,194 | $15.7K |
| Jan 26, 2026 | Zurbay Donald Director | Award | 6,871 | $0 |
| Jan 9, 2026 | Frohning Andrea L. SVP, CHRO | Award | 392 | $0 |
| Jan 9, 2026 | Deese Willie A Director | Award | 202 | $0 |
| Jan 9, 2026 | Czerney Kevin VP, Chief Accounting Officer | Award | 263 | $0 |
| Jan 9, 2026 | Barber Michael J Director | Award | 246 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for DENTSPLY SIRONA Inc.
Free account. Everything above stays public.
Write why you follow DENTSPLY SIRONA Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading